A chemotherapy-free, pathological response-adapted strategy using trastuzumab–pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study. - Garrigós, L.; Ruiz-Borrego, M.; Pérez-García, J.M.; Guerrero-Zotano, A.; Cortés-Salgado, A.; Kuemmel, S.; Colleoni, M.; Reboredo-Rendo, C.; Bermejo, B.; Blancas, I.; Gavila, J.; Fabi, A.; et al. (Annals of Oncology, 2026)